Parkinson’s disease-like midbrain hyperechogenicity is frequent in amyotrophic lateral sclerosis
- 382 Downloads
Clinical and neuroimaging data suggest impairment of the nigrostriatal system in amyotrophic lateral sclerosis (ALS). We thus hypothesized whether Parkinson’s disease (PD)-like midbrain sonography findings are also present in ALS. Eighty-six patients with the diagnosis of possible or definite ALS according to revised El Escorial criteria were examined by transcranial B-mode sonography compared to 76 age- and gender-matched controls and 33 PD patients. Hyperechogenic areas of the midbrain representing the substantia nigra were measured planimetrically using standard protocols. In subjects with sufficient temporal acoustic bone windows, mean midbrain hyperechogenic areas were significantly higher in ALS (0.251 ± 0.104 cm2) and PD patients (0.286 ± 0.078 cm2) compared to controls (0.091 ± 0.054 cm2) with no significant difference between ALS and PD patients (one-way ANOVA: F value = 94.3; P < 0.0001). Sixty-seven percent (95 % CI 57–78 %) of ALS patients and 84 % (95 % CI 71–97 %) of PD patients displayed abnormal midbrain hyperechogenic areas (P = 0.383 for group comparison, χ2 test). No correlations of hyperechogenic area sizes in ALS patients were found in regard to age, gender, ALS subtype (bulbar versus spinal form) or ALS-FRS-R score. In summary, we observed hyperechogenicity of the substantia nigra in patients with sporadic ALS with a frequency similar to that in PD and higher than in all other movement disorders. These findings are important for the diagnosis and differential diagnosis of PD and ALS alike.
KeywordsAmyotrophic lateral sclerosis Substantia nigra Parkinson’s disease Symptomatic therapy
We thank all the patients who participated in this study and acknowledge the enthusiastic help of Tordis Leimert.
Conflicts of interest
None of the authors reports any disclosures for this study.
The study was approved by the local ethics committees of the Universities of Ulm and Dresden.
- 3.Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (2008) The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study. Lancet Neurol 7(5):417–424. doi: 10.1016/S1474-4422(08)70067-X PubMedCrossRefGoogle Scholar
- 4.Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59(6):999–1005 noc10166 [pii]PubMedCrossRefGoogle Scholar
- 12.Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K, Schild L, Hengerer B, Ludolph AC, Dorner-Ciossek C, Kussmaul L (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-l-propylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 316(1):189–199. doi: 10.1124/jpet.105.092312 PubMedCrossRefGoogle Scholar